Advancing the Future of Biologic Delivery
Lindy Biosciences CEO Presents at Colorado Protein Stability Conference
CEO Deborah Bitterfield, PhD presented at the 2026 Colorado Protein Stability Conference, held August 3–6 at Beaver Run Resort in Breckenridge, CO, joining leading researchers from pharmaceutical science, industry, and the FDA.
Read moreDeborah Bitterfield Returns to CED Venture Connect as a Featured Presenter
CEO Deborah Bitterfield, PhD returned to CED Venture Connect (VC26) as a presenter in the Human Health – Biotech & Medtech session, held March 24–25 at the DPAC in Durham, NC.
Read moreLindy Biosciences CEO Featured in Investment Reports' New Era of Life Sciences
CEO Deborah Bitterfield sat down with Investment Reports as part of their New Era of Life Sciences series, explaining Lindy's drug delivery platform and the patient impact of subcutaneous administration.
Read moreLindy Biosciences Featured in SSTI's NCBiotech Spotlight
CEO Deborah Bitterfield was featured in a story from SSTI (State Science & Technology Institute) highlighting NCBiotech's TBED program and its impact on early-stage biotech companies in North Carolina.
Read moreLindy Biosciences Named Among Leading Biotech Companies in Research Triangle Park
Lindy Biosciences was featured by Built In in a roundup of notable biotech companies based in Research Triangle Park, NC, highlighting the region's growing life sciences ecosystem.
Read moreLindy Biosciences Heads to PODD 2025 for Drug Delivery Partnering
CEO Deborah Bitterfield and VP of Corporate Strategic Partnerships Neil Jones attended the 15th annual PODD Conference in Boston, October 27–28, exploring partnership opportunities across the drug delivery industry.
Read moreBuilding the Future Together: Deborah Bitterfield Panels at Venture Connect 2025
CEO Deborah Bitterfield joined the opening panel session — 'The Power of Connection: Building the Future Together' — at CED Venture Connect 2025 in Raleigh, NC, March 26–27. Lindy was also featured in GrepBeat's post-event highlights coverage.
Read moreLindy Biosciences Selects Lifecore Biomedical as CDMO Partner
Lindy Biosciences selected Lifecore Biomedical (Nasdaq: LFCR), a fully integrated CDMO, to support process development and commercial-scale manufacturing of its microglassification-based drug delivery platform.
Read moreLindy Biosciences Enters Licensing and Collaboration Agreement with Novartis
Lindy Biosciences entered a licensing and collaboration agreement with Novartis for multi-target drug delivery innovation — advancing self-administered biologic treatments using Lindy's drug delivery platform. Read the full press release for details.
Read moreDeborah Bitterfield Takes the Stage at CRS 2024 in Bologna
CEO Deborah Bitterfield, PhD attended and presented at Technical Session VII of the Controlled Release Society (CRS) Annual Meeting — #CRS2024 — held in Bologna, Italy.
Read moreLindy Biosciences Selected to Present at CED Venture Connect 2023
Lindy Biosciences was selected to present at the 39th annual CED Venture Connect Investor Conference. CEO Deborah Bitterfield presented during the drug delivery session on March 30, 2023, before an audience of angel and VC investors.
Read moreDeborah Bitterfield Joins Expert Panel at PODD 2022
CEO Deborah Bitterfield joined an expert panel at the 12th annual Partnership Opportunities in Drug Delivery (PODD) Conference in Boston, exploring emerging and established collaboration opportunities across the industry.
Read moreRedefining High-Concentration Formulations: Deborah Bitterfield at Bioprocessing Summit
CEO Deborah Bitterfield spoke at the 2022 Bioprocessing Summit in Boston in a session titled 'Redefining High-Concentration Formulations: Beyond the Aqueous Limit,' addressing the frontier of biologic drug formulation.
Read moreLindy Biosciences Raises $4.25M to Fuel Growth and Expansion
Lindy Biosciences raised more than $4.25 million, per an SEC filing, with plans to grow its team and relocate to a larger facility in the Research Triangle Park area.
Read morePartner or Peril: Lindy Biosciences CEO at the NACD Annual Meeting
CEO Deborah Bitterfield joined a boardroom panel at the National Association of Corporate Directors in a session titled 'Partner or Peril,' exploring how to build and sustain high-impact strategic partnerships.
Read moreLindy Biosciences Takes the Stage at CED Venture Connect 2022
CEO Deborah Bitterfield took the stage at CED's Venture Connect 2022 Summit to present Lindy's drug delivery platform technology to angel and VC investors, corporate partners, and the life sciences community.
Read moreLindy Biosciences Joins NCBIO's Academic Engagement Night
Lindy Biosciences exhibited at NCBIO's Academic Engagement Night, an event designed to introduce college students to the life sciences industry and the companies shaping its future.
Read more
